IGXT Archives - Page 5 of 8

Developments

IntelGenx grants Tetra Bio-Pharma additional rights to Adversa mucoadhesive delivery technology

IntelGenx (TSXV:IGX; OTCQB:IGXT) granted cannabinoid-derived drug developer Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF) additional exclusive worldwide rights to IntelGenx’s Adversa mucoadhesive delivery technology. Adversa...

October 20, 2020

Developments

IntelGenx’s two oral psychedelic film deals featured on FiercePharma

FiercePharma featured IntelGenx (TSXV:IGX; OTCQX:IGXT) and its two recent deals for the development of psychedelic oral films. In July and August, the company signed feasibility agreements with Cybin Corp. and ATAI Life...

September 16, 2020

Developments

IntelGenx, Exeltis expand RIZAPORT commercialization pact to include the EU

IntelGenx (TSXV:IGX; OTCQB:IGXT) granted its partner, Exeltis Healthcare, an exclusive license to manufacture and commercialize RIZAPORT in the EU. Under the accord, Exeltis will pay IntelGenx royalties on net RIZAPORT...

August 27, 2020

Developments

IntelGenx in feasibility pact with ATAI for film-based psychedelics

IntelGenx (TSXV:IGX; OTCQB:IGXT) and ATAI Life Sciences signed a feasibility agreement for the development of novel formulations of pharmaceutical-grade psychedelics, based on IntelGenx’s film technologies. Under...

August 20, 2020

Developments

IntelGenx and Tilray amend exclusivity of cannabis-infused VersaFilm accord

IntelGenx (TSXV:IGX; OTCQB:IGXT) and Tilray (NASDAQ:TLRY) amended the exclusivity terms of their November 2018 license, development and supply agreement to allow for IntelGenx’s co-development and commercialization of...

July 20, 2020

Developments

IntelGenx in feasibility pact with Cybin for fast-acting, orally-dissolving psilocybin film

IntelGenx (TSXV:IGX; OTCQB:IGXT) inked a feasibility agreement with Cybin for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin. Cybin is Canada’s premier mushroom...

July 7, 2020

Developments

IntelGenx pleased with FDA meeting on NDA resubmission for RIZAPORT VersaFilm

IntelGenx (TSXV:IGX; OTCQB:IGXT) obtained clarity on the chemistry, manufacturing and controls information required for the resubmission of its RIZAPORT VersaFilm NDA during its Type A meeting with the FDA on June 10...

June 11, 2020

Developments

IntelGenx receives Health Canada cannabis micro-processing license

IntelGenx (TSXV:IGX; OTCQB:IGXT) received a cannabis micro-processing license from Health Canada under the Cannabis Act and Cannabis Regulations for the company’s Montreal, Quebec facility. “Receipt of this cannabis...

June 8, 2020

Developments

IntelGenx schedules meeting with the FDA to discuss RIZAPORT NDA

The FDA has granted IntelGenx Technologies’ (TSXV:IGX; OTCQX:IGXT) request for a Type A meeting to discuss the company’s RIZAPORT VersaFilm program. The meeting is scheduled for June 10, 2020. On March...

May 27, 2020

Developments

IntelGenx adjusts VersaFilm business strategy

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) unveiled a series of initiatives aimed at helping the company address, and satisfactorily respond to, the complete response letter that it recently received from the FDA...

April 6, 2020

Tag - IGXT

IntelGenx grants Tetra Bio-Pharma additional rights to Adversa mucoadhesive delivery technology

IntelGenx’s two oral psychedelic film deals featured on FiercePharma

IntelGenx, Exeltis expand RIZAPORT commercialization pact to include the EU

IntelGenx in feasibility pact with ATAI for film-based psychedelics

IntelGenx and Tilray amend exclusivity of cannabis-infused VersaFilm accord

IntelGenx in feasibility pact with Cybin for fast-acting, orally-dissolving psilocybin film

IntelGenx pleased with FDA meeting on NDA resubmission for RIZAPORT VersaFilm

IntelGenx receives Health Canada cannabis micro-processing license

IntelGenx schedules meeting with the FDA to discuss RIZAPORT NDA

IntelGenx adjusts VersaFilm business strategy

General

More